REPLIGEN CORP Deferred Tax Liabilities, Gross
REPLIGEN CORP (RGEN) had Deferred Tax Liabilities, Gross of $120.18 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-02-26
- 2025-12-31: Deferred Tax Liabilities, Gross $120.18M.
- 2024-12-31: Deferred Tax Liabilities, Gross $127.55M.
- 2023-12-31: Deferred Tax Liabilities, Gross $121.56M; Deferred Tax Liabilities, Gross as first filed $120.05M.
- 2022-12-31: Deferred Tax Liabilities, Gross $92.62M; Deferred Tax Liabilities, Gross as first filed $91.00M.
| Period end | Deferred Tax Liabilities, Gross | Deferred Tax Liabilities, Gross as first filed |
|---|---|---|
| 2025-12-31 | $120.18M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $127.55M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $121.56M 10-K · filed 2025-03-14 | $120.05M 10-K · filed 2024-02-22 |
| 2022-12-31 | $92.62M 10-K/A · filed 2024-11-18 | $91.00M 10-K · filed 2023-02-22 |
| 2021-12-31 | $81.53M 10-K · filed 2023-02-22 | |
| 2020-12-31 | $47.27M 10-K · filed 2022-02-17 | |
| 2019-12-31 | $44.75M 10-K · filed 2021-02-24 | $46.96M 10-K · filed 2020-02-26 |
| 2018-12-31 | $31.33M 10-K · filed 2020-02-26 | $30.37M 10-K · filed 2019-03-01 |
| 2017-12-31 | $36.35M 10-K · filed 2019-03-01 | |
| 2016-12-31 | $13.39M 10-K · filed 2018-02-22 | |
| 2015-12-31 | $501.00K 10-K · filed 2017-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |